DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Katsutani S, Tomiyama Y, Kimura A. , et al.
Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.
Int J Hematol 2013;
98 (03) 323-330
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.